Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Ruxolitinib in Refractory NSCLC
NCT02145637Phase 1Completed
- Sponsor
- Yonsei University
- Start
- May 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Primary endpoint: Recommended Phase II Dose at 36 days. Started May 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02145637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145637.